Here are the 10-K annual reports from Caris Life Sciences, Inc. (CAI) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow CAI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CAI filings page.
Caris Life Sciences, Inc. describes a precision oncology business built on comprehensive molecular profiling and artificial intelligence. The company focuses on tissue- and blood-based sequencing to guide cancer diagnosis, therapy selection, minimal residual disease tracking, and early detection.
Caris reports sequencing over 1,000,000 oncology cases as of December 31, 2025 and serving more than 6,000 ordering physicians. Its MI Profile tissue platform, Caris Assure blood platform, and planned whole genome solutions, including the Caris Detect early detection assay expected in 2026, generate large multi-modal datasets used for clinical care, biopharma partnerships, and internal drug discovery.
The company highlights FDA-approved MI Cancer Seek as a WES/WTS companion diagnostic, growing Medicare and commercial coverage for Caris Assure, extensive intellectual property, and a global research network. It also notes a substantial biopharma services and data-licensing business built on its clinico-genomic and imaging datasets.